Skip to main content

Home/ TOK@ISPrague/ Group items tagged pharmaceutical

Rss Feed Group items tagged

Lawrence Hrubes

Ben Goldacre: Battling bad science | Video on TED.com - 0 views

  •  
    "Every day there are news reports of new health advice, but how can you know if they're right? Doctor and epidemiologist Ben Goldacre shows us, at high speed, the ways evidence can be distorted, from the blindingly obvious nutrition claims to the very subtle tricks of the pharmaceutical industry. Ben Goldacre unpicks dodgy scientific claims made by scaremongering journalists, dubious government reports, pharmaceutical corporations, PR companies and quacks."
Andrea Barlien

The Truth Wears Off - The New Yorker - 1 views

  •  
    On September 18, 2007, a few dozen neuroscientists, psychiatrists, and drug-company executives gathered in a hotel conference room in Brussels to hear some startling news. It had to do with a class of drugs known as atypical or second-generation antipsychotics, which came on the market in the early nineties. The drugs, sold under brand names such as Abilify, Seroquel, and Zyprexa, had been tested on schizophrenics in several large clinical trials, all of which had demonstrated a dramatic decrease in the subjects' psychiatric symptoms. As a result, second-generation antipsychotics had become one of the fastest-growing and most profitable pharmaceutical classes. By 2001, Eli Lilly's Zyprexa was generating more revenue than Prozac. It remains the company's top-selling drug.
  •  
    On September 18, 2007, a few dozen neuroscientists, psychiatrists, and drug-company executives gathered in a hotel conference room in Brussels to hear some startling news. It had to do with a class of drugs known as atypical or second-generation antipsychotics, which came on the market in the early nineties. The drugs, sold under brand names such as Abilify, Seroquel, and Zyprexa, had been tested on schizophrenics in several large clinical trials, all of which had demonstrated a dramatic decrease in the subjects' psychiatric symptoms. As a result, second-generation antipsychotics had become one of the fastest-growing and most profitable pharmaceutical classes. By 2001, Eli Lilly's Zyprexa was generating more revenue than Prozac. It remains the company's top-selling drug.
markfrankel18

Jaron Lanier on Lack of Transparency in Facebook Study - NYTimes.com - 0 views

  • SHOULD we worry that technology companies can secretly influence our emotions? Apparently so.
  • It is unimaginable that a pharmaceutical firm would be allowed to randomly, secretly sneak an experimental drug, no matter how mild, into the drinks of hundreds of thousands of people, just to see what happens, without ever telling those people. Imagine a pharmaceutical researcher saying, “I was only looking at a narrow research question, so I don’t know if my drug harmed anyone, and I haven’t bothered to find out.” Unfortunately, this seems to be an acceptable attitude when it comes to experimenting with people over social networks. It needs to change.
  • Research with human subjects is generally governed by strict ethical standards, including the informed consent of the people who are studied. Facebook’s generic click-through agreement, which almost no one reads and which doesn’t mention this kind of experimentation, was the only form of consent cited in the paper. The subjects in the study still, to this day, have not been informed that they were in the study. If there had been federal funding, such a complacent notion of informed consent would probably have been considered a crime. Subjects would most likely have been screened so that those at special risk would be excluded or handled with extra care.
  • ...1 more annotation...
  • Stealth emotional manipulation could be channeled to sell things (you suddenly find that you feel better after buying from a particular store, for instance), but it might also be used to exert influence in a multitude of other ways.
markfrankel18

Meet the anti-Dr. Oz: Ben Goldacre - Vox - 0 views

  • Over the years, Goldacre has taken on everyone from sloppy journalists to pharmaceutical executives, vitamin proprietors, and disingenuous academics. He has illuminated the evidence, and lack thereof, behind detox footbaths, homeopathy, and ear candling. And, with every debunking, he has left behind lessons in the scientific method, epidemiology, and evidence-based medicine. His writing has changed policy and informed the public at a time when few in the media stand up for science in health.
  • Giving people a ten-point plan about how to spot bad science isn’t going to help those people because they probably don’t care about science. I don’t think you can reason people out of positions they didn’t reason themselves into.
Lawrence Hrubes

BBC News - Should drug firms make payments to doctors? - 1 views

  • Using data from more than 330,000 doctors and 12 pharmaceutical firms, it identified 58% as having received payments. It found that payments were unlikely to represent significant opportunities to educate doctors about new drugs, and that financial gain appears to be an important motive for doctors. Daniel Carlat, director of the prescription project at the non-profit group Pew Trusts, says research to date shows that doctors who have dealings with drugs reps "tend to prescribe differently". "They prescribe more drugs, more expensive drugs, more brand-name drugs, and they're less likely to follow evidence-based practice guidelines in prescribing drugs.
Lawrence Hrubes

Prison Architecture and the Question of Ethics - NYTimes.com - 1 views

  • Today, prison design is a civic cause for some architects who specialize in criminal justice and care about humane design. There is a lot of research documenting how the right kinds of design reduce violence inside prisons and even recidivism. Architects can help ensure that prisons don’t succumb to our worst instincts — that they are not about spending the least amount of money to create the most horrendous places possible, in the name of vengeance — but promote rehabilitation and peace.Designing execution chambers is something else. They require their own deathly architecture. If architects refuse to design them, that doesn’t mean that they won’t be built, any more than the refusal by doctors and pharmaceutical companies to participate in executions has stopped executions from happening. But Ms. Dreiling said it herself: “Many, if not most, architects enter this profession because it is a calling. They believe they can make the world a better place, they believe they can enhance the lives of people on a daily basis, where they live, work and play.”
1 - 6 of 6
Showing 20 items per page